Skip to Main Content

The first clinical trial of CRISPR-Cas9 sponsored by U.S. companies has launched, testing the genome-editing technique in patients with the blood disorder beta thalassemia, according to an announcement posted Friday on the U.S. clinical trials website.

The Phase 1/2 clinical trial, co-sponsored by Vertex Pharmaceuticals and using an experimental treatment from CRISPR Therapeutics, will be conducted at a single hospital in Regensburg, Germany, and aims to recruit up to 12 adults with the inherited disease. Although it was only a matter of time before the start of the first company-sponsored CRISPR clinical trial, Editas Medicine’s experimental treatment for a rare form of blindness was widely expected to be the first in the clinic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
    • We would appreciate it if you would notify us about this clinical trial as we are following many patients suffering hemoglobinopathies at the Hereditary Blood Disorders Clinic and Research Team at the National Research Centre in Egypt
      Obliged

Comments are closed.